These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
688 related articles for article (PubMed ID: 28596304)
21. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]
22. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068 [TBL] [Abstract][Full Text] [Related]
23. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events. Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008 [TBL] [Abstract][Full Text] [Related]
24. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916 [TBL] [Abstract][Full Text] [Related]
25. Reduction of cardiovascular risk with evolocumab (Repatha). Med Lett Drugs Ther; 2017 Apr; 59(1519):63-64. PubMed ID: 28419071 [No Abstract] [Full Text] [Related]
26. Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Leiter LA; Zamorano JL; Bujas-Bobanovic M; Louie MJ; Lecorps G; Cannon CP; Handelsman Y Diabetes Obes Metab; 2017 Jul; 19(7):989-996. PubMed ID: 28206704 [TBL] [Abstract][Full Text] [Related]
27. PCSK9 inhibition and inflammation: A narrative review. Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822 [TBL] [Abstract][Full Text] [Related]
28. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843 [TBL] [Abstract][Full Text] [Related]
36. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications. Cokkinos DV; Cokkinos P; Kolovou G Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741 [No Abstract] [Full Text] [Related]